noisi quarter mid-point ep guid increas
view report ep street expect
solid demand sale momentum opinion though
creat nois organ growth rate
result report adjust ep
estim street total adjust revenu
y/i includ divestitur restat
organ basi absolut revenu total
estim adjust ebitda margin
estim attribut modest beat
oper factor given upsid ebitda
organ growth total compani organ revenu growth deceler
y/i prior quarter organ growth acceler if
deceler gf
time confer call manag note
underli demand busi solid sale momentum
remain strong compani ad backlog achiev
double-digit sale growth quarter
y/i sharp deceler last quarter accord
compani organ growth declin
stem time differ licens renew
revers especi declin
furthermor stem client opt outsourc deal
integr financi solut if organ revenu growth
versu last quarter gener reflect mix cost
initi if ebitda margin expand y/i last quarter
forecast
guidanc manag increas midpoint ep guidanc
rang put ep
current street consensu revenu ep
low attribut mid-point ep increas oper
tweak ep estim maintain target price
quarter tweak ep estim one penni higher
reduc despit decreas
forward estim maintain target price
estim discount closest competitor given organ
growth execut differ
price intra-day et
revenu pleas note re-stat
remain origin report
ep cash dilut pleas note
re-stat remain origin
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
believ compani focu turn acceler
revenu growth balanc margin especi given
focu larger transform deal global f/i
channel opinion compani intern exposur
repres competit advantag especi deal size
appear increas fintech spend becom
strateg els equal posit trend continu
believ multipl expans possibl futur
near term compani could face pressur
macro-environ increas competit
time differenti given shift larger integr
contract risk associ exposur big
near-term potenti catalyst includ improv
expans project ramp global f/i channel
impact fintech innov mobil real-tim
network cross-sel sungard acquisit
bloomberg capit market estim upside/downside/target
price target roughli
ep estim line histor averag
discount target multipl closest competitor
given organ growth execut differ underli
ep estim expect organ growth
mid-singl digit base low-single-digit growth overal
bank tech spend price target support outperform
upsid scenario valuat upsid
ep estim premium current estim
one-point premium target multipl believ
appropri earn surpris upsid
upsid potenti assum acceler organ growth
high-singl digit driven increas bank technolog
spend fidel client win end
potenti intern demand perhap form
larg contract oper leverag
downsid scenario valuat base
downsid ep estim discount current estim
five-point reduct target multipl
believ appropri earn surpris downsid
would call question stabil compani
potenti assum deceler organ growth driven
whether fidel client lose end potenti
report adjust ep estim
street total adjust revenu y/i includ divestitur restat
organ basi absolut revenu total
estim revenu expect integr solut if
global solut gf
adjust ebitda margin estim
attribut modest beat oper factor given upsid ebitda
addit result would highlight follow
total compani organ revenu growth deceler y/i prior
quarter organ growth acceler if deceler gf
time confer call manag note
underli demand busi solid sale momentum remain
strong compani ad backlog achiev double-digit sale
growth quarter
guidanc manag increas midpoint ep guidanc
rang put ep current street consensu
revenu ep low attribut mid-point ep
increas oper out-performance reflect demand improv volum
increas if organ growth guidanc time
effect licens sale shift outsourc result reduct gf
organ growth guidanc
deceler last quarter deceler organ growth institut
wholesal versu last quarter bank payment busi also
deceler adjust ebitda margin expand y/i
last quarter mix oper improv synergi divestitur
estim forecast accord compani
organ growth declin stem time
differ licens renew revers especi
declin furthermor stem client opt outsourc deal
decreas revenu near term improv visibl
integr financi solut if organ revenu growth versu last
quarter unit saw modest deceler bank wealth organ growth
last quarter revers payment organ revenu increas
versu declin last quarter adopt volum increas
acceler corpor digit organ growth last quarter
termin fee versu last year manag guid
termin fee rel flat previou year gener
reflect mix cost initi if ebitda margin expand y/i
last quarter forecast
free cash flow capit redeploy free cash flow quarter
quarter compani paid dividend repurchas share
year-to-d juli repurchas share
manag tighten ep guidanc toward higher end leav
organ revenu growth unchang
 if organ revenu growth increas
 gf organ revenu growth revenu declin
reduc
adjust ebitda margin rang
 adjust ep
exhibit earn summari comparison million except per share amount
estimate actualdelta/ deltaactu expens tax rate net vs expectationsprior year payment processor servic
price target roughli ep estim line histor
averag discount target multipl closest competitor given organ
growth execut differ underli ep estim expect organ
growth mid-singl digit base low-single-digit growth overal bank tech spend
price target support outperform rate
risk rate price target
lack growth bank spend contempl model inabl
cross-sel new product could imped price target object rate continu
consolid bank failur prolong global recess could caus stock perform
expect imped achiev price target object rate
lead provid technolog solut process servic information-bas
servic financi servic industri compani process technolog
relationship custom countri custom rang
larg financi institut small credit union
ep model million except per share amount
total
total
corpor
gf
corp
corpor
compani data capit market estim ep exclud purchas amort non-cash expens
